About Clinical Trials

Hundreds of clinical trials throughout the United States are currently being held to evaluate immunotherapy drugs as new treatments for melanoma, in combination with other strategies or as new uses for existing treatments. New participants are needed for these studies to succeed, but many patients are fearful of participating in clinical trials. Health care professionals can be instrumental in influencing and encouraging patient participation.

Encourage Patients to Try Clinical Trials

Offer these reasons for why a patient should consider participating in a clinical trial:Tip.jpg

  1. A clinical trial may offer a worthwhile alternative to a treatment that is not working as well as expected.
  2. A clinical trial may significantly improve the patient’s quality of life. Discuss the advantages and disadvantages of participating, especially addressing any concerns about side effects.
  3. Tell patients they will not only help identify treatments that work, they’ll help eliminate those that don’t. Patients likely don’t realize the integral role they play in helping refine and improve the way millions of people with all types and stages of melanoma are treated.
  4. Educate them about how treatments become approved by the U.S. Food and Drug Administration by telling them every treatment available today went through clinical trials to get FDA approval.
  5. Assure your patients that they will be treated with dignity and respect and will receive the highest quality of care for melanoma.

Getting Started

To be eligible for an immunotherapy clinical trial, a patient must have a properly functioning immune system. In addition, the patient must meet certain eligibility criteria (cancer type, overall health, treatment history, etc.).

Current clinical trials using immunotherapy for melanoma with open recruitment as of September 16, 2016, are displayed in the Immunotherapy for the Treatment of Melanoma for Health Care Professionals. Each trial listed is categorized as “cancer immunotherapy” on www.clinicaltrials.gov.

Encourage patients to keep researching available trials, especially if they locate a clinical trial that is not recruiting in their area. Remind them that new studies and new phases are happening all the time.

Share this information with your patient and explain how to learn about a specific trial with these instructions:

[1] Visit www.clinicaltrials.gov.  [2] Enter the trial record number into the search box located at the top of the Web page. The trial record number is a unique identification code assigned to each clinical study.  [3] The trial will be “Recruiting” or “Not yet recruiting,” which means the studies are either actively looking for participants or getting ready to look for participants.

©Patient Resource

Open Forum Discussions

  • Princeton Center for Theoretical Science presents the 2019 Distinguished Visiting Lecturer Aleksandra Walczak Laboratoire de Physique Théorique Ecole Normale Supérieure Public ...

  • 2019 Annual Cancer Treatment-Related Adverse Events Symposium Friday-Saturday, October 25-26, 2019 Memorial Sloan Kettering Cancer Center  Register online: http://www.mskcc.org/AdverseEvents ...

  • Dear colleagues, I would like to personally invite you to join Kim Margolin, MD, Ahmad Tahini, MD, PhD, and myself for SITC Webinar: I-O Highlights from ASCO 2019 , a free SITC webinar ...

  • https://biotrac.com/immune_oncology/ Bio-Trac® Multiplex Immunofluorescence in Immune Oncology Four Day Symposium and Workshop program divided ...

    1 person recommends this.
  • For those of you in the Philadelphia area, CAR-T and The Rise of the Cellicon Valley Thursday, May 9 and Friday, May 10, 2019 World experts in CAR T-cellular therapy and hematopoietic ...

SITC Resources

Oct 1, 2019 10:09 AM
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ESMO Congress 2019 held in Barcelona, Spain. SITC CONNECT Account A SITC Cancer Immunotherapy CONNECT account is required to view past meeting highlights.  Click ...
Sep 18, 2019 5:21 PM
Adrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. The authors investigated the efficacy and safety of pembrolizumab in patients with metastatic ACC. They concluded that single-agent pembrolizumab has modest ...
Sep 13, 2019 3:45 PM
Immune checkpoint inhibitors (ICIs) confer a survival benefit in many cancer types. Given that the survival outcome for cancer of unknown primary site (CUP) remains poor, the authors investigated the potential of CUP for immunotherapy. The authors conclude that the survival outcome of CUP remains unsatisfactory. ...
Sep 13, 2019 1:12 PM
The authors present  a case of sequential immune-related adverse events (irAEs) in a patient with metastatic melanoma treated with single-agent anti-programmed cell death-1 (PD-1) therapy, pembrolizumab. Although numerous cases of irAEs have been reported, sequential multi-organ involvement, including ...
Sep 13, 2019 1:09 PM
Hypophysitis is a well-recognized immune-related adverse event in patients treated with immune checkpoint inhibitors for cancer. Some anterior pituitary hormones may recover; however, secondary adrenal insufficiency is usually permanent. This case documents an unusual recovery from secondary adrenal ...
Sep 13, 2019 1:05 PM
There is strong evidence that immunotherapy-mediated tumor rejection can be driven by tumor-specific CD8+ T cells reinvigorated to recognize neoantigens derived from tumor somatic mutations. Thus, the frequencies or characteristics of tumor-reactive, mutation-specific CD8+ T cells could be used as biomarkers ...